[Occlusion of the PreserFlo® MicroShunt Implant by Iris Tissue]
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Ahmed T, Honjo M, Sakata R, Fujishiro T, Shirato S, Aihara M
. Long-term results of the safety and effectiveness of a novel microshunt in Japanese patients with primary open-angle glaucoma. Jpn J Ophthalmol. 2022; 66(1):33-40.
DOI: 10.1007/s10384-021-00893-x.
View
2.
Batlle J, Corona A, Albuquerque R
. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study. J Glaucoma. 2020; 30(3):281-286.
PMC: 8041565.
DOI: 10.1097/IJG.0000000000001734.
View
3.
Beckers H, Aptel F, Webers C, Bluwol E, Martinez-de-la-Casa J, Garcia-Feijoo J
. Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study. Ophthalmol Glaucoma. 2021; 5(2):195-209.
DOI: 10.1016/j.ogla.2021.07.008.
View
4.
Tan A, Webers C, Berendschot T, de Brabander J, de Witte P, Nuijts R
. Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber. Acta Ophthalmol. 2016; 95(1):91-96.
PMC: 5298043.
DOI: 10.1111/aos.13161.
View